Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

trialsTrialRecruiting

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

A phase 2 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and QL1706 in colorectal cancer, run by Fujian Cancer Hospital, now recruiting.

Overview Connected8

Overview

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases is a phase 2, interventional study registered as NCT06787183 by Fujian Cancer Hospital, with a registry enrolment figure of 42 participants, started 2025-12-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Short course radiotherapy; Capecitabine; Oxaliplatin; QL1706. Conditions listed: Locally Advanced Rectal Cancer With Liver Metastases. Primary outcome: Progression-free-Survival. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal cancer with liver metastases (stage M1)". Sites: China. No results are recorded here; the registry entry is the source.

Setting

A Phase II Multicenter Clinical Trail of Efficacy and Safety of Short Course Radiotherapy Combined With CAPOX and PD-1/CTLA-4 Bispecific Antibody QL1706 in Patients With Liver Metastases From Rectal Cancer

Phase

Phase 2

Sponsor

Fujian Cancer Hospital

Registry

Enrolled

42 enrolled

Connected

Similar pages

not linked directly; found by shared links

Trial
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Trial
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant T
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.

cancers

1

technologies

3

Cytotoxic chemotherapy IMRT / IGRT (modern external beam)Platinum agents

drugs

3

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedCytotoxic regimen

FOLFOX (5-FU, leucovorin, oxaliplatin)

Phase 3bifunctional antibody mixture (iparomlimab and tuvonralimab; INN stem -mab)

terms

1

Colorectal cancer trials open today (registry snapshot)

Evidence strength28/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
42 enrolled+8
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources & links

ClinicalTrials.gov NCT06787183

colorectal-deep-dive

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Rectal cancer

Technologies

Cytotoxic chemotherapy
IMRT / IGRT (modern external beam)
Platinum agents

Products

Capecitabine
FOLFOX (5-FU, leucovorin, oxaliplatin)
QL1706

Machine-readable versions of SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06787183/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06787183.

WebMCP tools registered on this page: onco_search, onco_get_entity.